September 30, 2021 01:18 PM EDT
Manufacturing

Eli Lil­ly is­sues re­sponse to Form 483 at In­di­anapo­lis plant

Josh Sullivan

Af­ter an Aug. 12 dat­ed Form 483 called out Eli Lil­ly’s In­di­anapo­lis ster­ile in­jecta­bles plant for sev­er­al laps­es in qual­i­ty, the com­pa­ny has is­sued a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 100: The biotech in­dus­try braces for Trump 2.0

Lil­ly’s oral SERD makes strides in breast can­cer with Phase 3 da­ta

Ex­clu­sive: Bain-backed mus­cu­loskele­tal biotech rais­es $120M for trio of clin­i­cal-stage bi­o­log­ics

Chro­ma, Nvel­op merge to form nChro­ma Bio, rais­ing $75M to en­ter the clin­ic

Q32 Bio’s stock crash­es af­ter atopic der­mati­tis fail, alope­cia tri­al sna­fu

sponsored

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

A service from the Financial Times